Monday, October 7, 2024
HomeWell MindPsychologyHow do genetics contribute to the development of depression?

How do genetics contribute to the development of depression?

A recent study examined the effects of genes, specifically polygenic in nature, on the development of depression, as well as its severity and age of onset.

 

Depression, one of the most common mental health disorders in the world, is believed to develop as a result of both genetic and environmental factors. As technology improves, it becomes possible to study genetic factors with greater accuracy.

To this date, many parts of the human genome have been linked to a certain degree with the development of depression. As researchers began understanding that no one gene is entirely responsible for the development of the disorder, it became more likely that depression is polygenic in nature.

Depression may be affected by many genes

Polygenic means that genetics account for the development of depression through the influence of several hundred (or thousands) of genetic variants, each contributing with a small effect.

A large study analyzed data from a Danish sample of over 34,000 individuals. They aimed at determining the contribution of genes, polygenic in nature, to the development of depression in the larger population. This contrasts previous studies which aimed at determining how it influences the recurrence and maintenance of depression.

As published in JAMA Psychiatry, they further set out to investigate the contribution of polygenetic factors to severity and age-of-onset of the first episode of depression. The researchers have also investigated the association of bipolar disorder and schizophrenia with depression.

Clear contribution of polygenic factors

The results showed that there was a clear contribution of polygenic factors to the development of depression. The hazard of depression increased significantly the more genetic liability a person carried. The top 10% (in terms of liability) of the sample had a 2.55 times higher risk than the bottom 10%.

There has been a smaller association between bipolar and schizophrenia disorders. The association with age of onset and severity were likewise small. The latter is inconsistent with previous studies of genetics. It may be due to employing different measurements of severity, as well as genetic factors not yet accounted for by research.

The strengths of this study lie in the number of participants, as well as participants being selected from clinical records, as opposed to specific recruitment. The results are, however, tainted by the fact that the sample only refers to individuals with depression who are treated in hospitals. They do not reflect the untreated part of the population, as well as those treated by general practitioners (accounting for 85% of patients). Thus, it reflects the more severe cases of depression. Nevertheless, this study considerably contributes to our understanding of the role of genetics in the development of mental illness, particularly depression.

Written by Maor Bernshtein

Reference: Musliner, K. L., Mortensen, P. B., Mcgrath, J. J., Suppli, N. P., Hougaard, D. M., Bybjerg-Grauholm, J., . . . Agerbo, E. (2019). Association of Polygenic Liabilities for Major Depression, Bipolar Disorder, and Schizophrenia With Risk for Depression in the Danish Population. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2018.4166

Maor Bernshtein
Maor Bernshteinhttps://pathwaytoself.ca/
Maor is a Registered Social Worker and a Psychotherapist, specializing in mental health and trauma treatment. He holds a Master's degree in Social Work from the University of Western Ontario. Maor is passionate about helping make knowledge, tools, and support accessible to people from all walks of life. He continues to value the importance of accessibility and recognizing barriers by providing relational, collaborative mental health therapy.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

ANKTIVA Boosts BCG for Bladder Cancer

The FDA has approved the immunotherapy-boosting drug, ANKTIVA, to be used with the existing immunotherapy drug, Bacillus Calmette-Guerin (BCG). This new therapy is a...

Joke Of The Day

Patient: Do you really think I need to see a heart specialist? Doctor: Not really, but your insurance will cover it, and he is a friend of...

ADVERTISE WITH US

error: Content is read-only and copy-protected.